Big Brains
Psychedelics Without Hallucinations: A New Mental Health Treatment? with David E. Olson
Jan 11, 2024
David E. Olson, founding director of the UC Davis Institute of Psychedelics and Neurotherapeutics, discusses the potential of developing non-hallucinogenic psychedelics for mental health treatment. The podcast explores the therapeutic effects of psychedelics on neuropsychiatric diseases and the need for rapid and effective treatments. The development of novel compounds called cycloplastogens, which promote neuronal growth, is also discussed along with the accessibility of psychedelic therapies and clinical trials.
32:26
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Research is being conducted to develop non-hallucinogenic psychedelics for the treatment of mental illnesses, offering safer and more accessible options.
- Psychedelics like ketamine, LSD, and MDMA have rapid and sustained effects on structural plasticity, promoting the regrowth of damaged neural circuits.
Deep dives
Psychedelics as a Treatment Option for Mental Illness
Psychedelic drugs are being reconsidered as a potential treatment for depression and mental illnesses. Researchers are finding that substances like psychedelic mushrooms have shown promise in conjunction with therapy for treating depression, anxiety disorders, headache disorders, and substance use disorders. The Institute for Psychedelics and Neurotherapeutics is exploring the use of compounds like psilocybin, MDMA, and ketamine, reverse engineering them to enhance their therapeutic potential. The goal is to create drugs that can provide the neurophysiological benefits of psychedelics without the hallucinogenic effects, making them safer and more accessible for addressing the global mental health epidemic.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
